ERP & fMRI Biomarkers of NMDA-Receptor Hypofunction in Schizophrenia & the CHR for Psychosis

ERP and fMRI Biomarkers of NMDA-Receptor Hypofunction in Schizophrenia and the Clinical High Risk for Psychosis Syndrome: Evidence From Ketamine Challenge Studies
Speaker:
Daniel H. Mathalon, PhD, MD
Professor in Residence • Deputy Vice Chair for Research • Co-Director, Brain Imaging and EEG Laboratory • Dept. of Psychiatry and Behavioral Sciences • UCSF Weill Institute for Neuroscience
______________
Learning objectives:
• Discuss the clinical definition of the clinical high risk (CHR) for psychosis syndrome and its distinction from full-blown psychotic disorders, principally schizophrenia
• Discuss EEG-based ERP components MMN and P300, their abnormalities in schizophrenia and the CHR syndrome, and their prediction of clinical outcomes in CHR individuals
• Discuss fMRI-based thalamic connectivity, its abnormality in schizophrenia and the CHR syndrome, and its prediction of clinical outcomes in CHR individuals
• Discuss the rationale for pharmacological challenge studies with ketamine as a model of glutamatergic NMDA receptor hypofunction and the acute effects of ketamine on MMN, P300, and thalamic connectivity
_______________
UCSF Department of Psychiatry and Behavioral Sciences Grand Rounds presentations are for educational purposes and intended only for behavioral/mental health professionals and clinical providers